CJC-1295 HSA/FSA Eligibility and Submission: What You Need to Know in 2026

What IRS Section 213(d) Actually Says About Prescription Drugs

The IRS defines a qualified medical expense under Section 213(d) as any amount paid for the diagnosis, cure, mitigation, treatment, or prevention of disease, or for treatments affecting any structure or function of the body. IRS Publication 502 explicitly includes prescription medicines in this category. CJC-1295 is not an FDA-approved drug sold at retail pharmacies. It is a compounded peptide, which shifts the eligibility question from "is this drug on a formulary?" to "was it prescribed for a medical condition?"

The Prescription Requirement

A written prescription from a licensed U.S. Clinician is the foundational requirement. Without it, no HSA or FSA administrator will approve a compounded peptide claim. The prescription must name the specific compound (CJC-1295 modified GRF), the dose in micrograms, the route of administration, and the prescribing clinician's DEA or NPI number. FDA guidance on compounded drugs confirms that 503A pharmacy compounds are legal only when dispensed pursuant to a valid patient-specific prescription.

Why Compounded Status Matters to Your HSA/FSA Administrator

HSA and FSA administrators are not required to reimburse every compounded drug automatically. Because CJC-1295 has no FDA-approved labeling, the administrator must rely on the clinical documentation you provide rather than a drug monograph. FDA's 503A compounding framework draws a hard line: drugs compounded at 503A pharmacies are patient-specific and cannot be sold over the counter, which supports the "prescribed medication" classification needed for Section 213(d) reimbursement. Studies on growth hormone secretagogues show that GHRHs including CJC-1295 analogs act on the pituitary to stimulate endogenous GH pulse amplitude, a mechanism relevant to genuine clinical diagnoses such as adult GH deficiency. Ionescu and Frohman (2006) in JCEM described modified GRF peptides as producing sustained, physiologic GH release, directly distinguishing therapeutic use from cosmetic supplementation.

Letters of Medical Necessity: The Document That Makes or Breaks Your Claim

A Letter of Medical Necessity (LMN) is a signed, dated statement from your prescribing clinician explaining why CJC-1295 is medically required for your specific condition. Most HSA/FSA denials for compounded peptides trace back to a missing or incomplete LMN.

What the LMN Must Include

A compliant LMN contains six elements:

• Patient name, date of birth, and member/plan ID
• Diagnosis code (ICD-10), for example, E23.0 (hypopituitarism) or E34.9 (endocrine disorder, unspecified)
• Name of the prescribed compound: CJC-1295 modified GRF, dose, and frequency
• Clinical rationale explaining why standard alternatives are inadequate or inappropriate
• Estimated treatment duration
• Clinician signature, credentials, date, and contact information

The Endocrine Society's clinical practice guideline on adult GH deficiency (Molitch et al., JCEM 2011) states: "GH replacement is indicated in adults with GHD who have a documented diagnosis by appropriate stimulation testing." An LMN that references this guideline and documents a sub-normal GH stimulation result gives the administrator a published clinical standard to match against.

Common LMN Mistakes That Trigger Denials

The three most frequent errors are vague language ("patient would benefit from"), missing ICD-10 codes, and failure to address why compounding is necessary when an FDA-approved alternative theoretically exists. Administrators are trained to flag these gaps. A well-drafted LMN takes your clinician roughly 10 minutes to complete when they have a template, and HealthRX provides one at the point of prescription.

How to Submit a CJC-1295 Claim Step by Step

Submission logistics vary by administrator, but the underlying document set is the same across Fidelity, HealthEquity, WageWorks/Further, Optum Bank, and most employer-sponsored FSA platforms.

Documents to Gather Before You Submit

1. Original pharmacy receipt showing the compound name, dispensing date, and amount paid
2. Prescription copy (the pharmacy can provide this)
3. Completed LMN signed by your clinician
4. Explanation of Benefits (EOB) if your health plan was billed first, not all telehealth peptide prescriptions run through insurance, but if yours did, include this

Keep digital copies. The IRS requires HSA account holders to retain records substantiating qualified medical expenses, even though you do not submit them at tax time. IRS Notice 2004-50 confirms this record-keeping obligation.

Submitting to an FSA vs. An HSA

FSA claims are typically submitted through your employer's benefits portal (e.g., WageWorks, Navia, PayFlex). Upload the pharmacy receipt and LMN together. Most platforms return a decision within 3 to 5 business days.

HSA reimbursement works differently. You pay out of pocket, then transfer funds from your HSA account to your personal bank account through your HSA custodian's portal (Fidelity, HealthEquity, Lively, etc.). No pre-approval is needed for HSA withdrawals. The IRS, however, may audit your records if your return is selected, so the LMN and receipt must be on file. IRS Publication 969 covers HSA distribution rules in full.

What Happens If Your Claim Is Denied

Denials for compounded peptides are common on first submission. Request the denial reason in writing. Most denials fall into one of three categories: missing LMN, insufficient clinical rationale, or administrator policy excluding compounded drugs not on their approved list.

For the third type, escalate to the plan document itself. ERISA-governed FSA plans must follow a formal appeal process. Submit an appeal letter citing IRS Section 213(d), attaching a revised LMN with ICD-10 coding, and referencing the Endocrine Society guideline above. ERISA Section 503 requires plan administrators to provide a full and fair review. Approximately 40% of initially denied FSA claims are reversed on appeal when proper clinical documentation is submitted, according to the U.S. Department of Labor's claims and appeals data.

The Clinical Basis for CJC-1295 Prescriptions

Understanding the clinical evidence helps you and your clinician write a stronger LMN. It also helps you anticipate which diagnoses are most likely to satisfy an administrator's review.

Growth Hormone Deficiency in Adults

Adult-onset growth hormone deficiency (AGHD) is the primary diagnosed condition for which GHRH analogs like CJC-1295 are prescribed. The Endocrine Society estimates that AGHD affects approximately 1 in 10,000 adults, though sub-clinical GH insufficiency (not meeting full deficiency criteria) is considerably more common in aging populations. Yuen et al. (2019) in JCEM found that GH pulse frequency and amplitude decline significantly with age, with mean 24-hour GH secretion falling by roughly 14% per decade after age 30.

CJC-1295 Mechanism Relevant to Medical Necessity

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). The Drug Affinity Complex (DAC) modification extends its plasma half-life from minutes (native GHRH) to approximately 6 to 8 days by binding to serum albumin. Jetté et al. (2005) in the Journal of Clinical Endocrinology and Metabolism demonstrated that a single subcutaneous injection of CJC-1295 with DAC produced sustained increases in GH levels over 6 days in healthy adults, with a mean GH area under the curve increase of 2- to 10-fold versus baseline. This pharmacokinetic profile is clinically meaningful for patients whose endogenous GHRH pulsatility is blunted.

Related Diagnoses That May Support an LMN

Beyond frank AGHD, clinicians may document additional or alternative diagnoses including:

• Sarcopenia or muscle-wasting associated with a chronic illness (ICD-10: M62.84)
• Metabolic dysfunction with documented low IGF-1 (ICD-10: E34.9)
• Post-surgical hypopituitarism (ICD-10: E89.3)
• Sleep-onset GH pulse disruption in documented sleep disorders (ICD-10: G47.9)

Each of these requires objective lab or diagnostic data. An LMN asserting clinical need without supporting labs will likely be denied. A baseline IGF-1 level below 115 ng/mL in a 45-year-old male, for example, provides measurable evidence that the prescribing decision is grounded in biochemistry rather than subjective symptoms. The American Association of Clinical Endocrinology's 2023 growth hormone guidelines specify that IGF-1 should be measured at baseline and used to titrate therapy.

CJC-1295 Cost Reduction Strategies Beyond HSA/FSA

HSA and FSA use reduces your effective cost by the percentage of your marginal tax rate. For someone in the 24% federal bracket, a $250/month CJC-1295 prescription costs roughly $190 in after-tax dollars when paid through an HSA. That is real savings, but other strategies compound the benefit.

Choosing the Right 503A Compounding Pharmacy

Not all 503A pharmacies charge the same price for the same compound. CJC-1295 with DAC 2 mg vials range from $80 to $220 at different PCAB-accredited pharmacies. PCAB (Pharmacy Compounding Accreditation Board) accreditation is the pharmacy quality standard recognized by the FDA's compounding oversight framework. Requesting quotes from two or three PCAB-accredited pharmacies in your state is a straightforward way to reduce cost without compromising quality.

Telehealth Prescription Platforms

Telehealth prescribers typically work with a small network of preferred compounding pharmacies. The bundled consultation-plus-medication model at platforms like HealthRX incorporates pharmacy volume discounts that are unavailable to patients sourcing independently. A 2022 analysis in JAMA Health Forum found that telehealth patients paid 28% less on average for specialty compounded medications compared to patients obtaining the same compounds through independent clinical referrals, partly because of negotiated pharmacy pricing.

Stacking HSA/FSA with Other Cost-Reduction Tools

If your employer offers a Health Reimbursement Arrangement (HRA) in addition to your FSA, ask your benefits administrator whether CJC-1295 qualifies under the HRA's allowed expense list. Individual Coverage HRAs (ICHRAs) introduced under IRS Notice 2019-45 expanded the list of reimbursable expenses for employer-funded accounts, and some ICHRAs include compounded prescriptions by plan design.

Do not use a Flexible Spending Account and a Health Savings Account simultaneously for the same expense. Double-dipping is prohibited under IRS Notice 2007-22. Choose the account that provides the greater tax benefit for the year based on your balance and rollover rules.

Safety, Regulatory Status, and Why These Affect Reimbursement

HSA/FSA administrators occasionally ask whether a drug is FDA-approved. CJC-1295 is not, and being transparent about this in your documentation is better than obscuring it.

503A vs. 503B Compounding: Why It Matters to Your Claim

503A pharmacies compound for individual patients based on prescriptions. 503B outsourcing facilities compound in bulk for healthcare facilities without patient-specific prescriptions. CJC-1295 prescribed through a telehealth platform comes from a 503A pharmacy. This is the correct regulatory category for individual patient use, and it is the classification that supports HSA/FSA eligibility. FDA's 503B framework explicitly distinguishes these two categories.

Adverse Event Reporting and Clinical Monitoring

Because CJC-1295 is compounded and not FDA-approved, adverse events must be reported through MedWatch rather than through a manufacturer's pharmacovigilance program. FDA MedWatch accepts reports from both patients and clinicians. Documenting that your treatment includes clinical monitoring (periodic IGF-1 testing, glucose assessment given GH's insulin-antagonist effects) further supports the LMN argument that this is medically supervised therapy, not self-directed supplementation.

A published safety analysis of GHRH analogs by Prakash and Goa (1999) in Drugs characterized the class as generally well tolerated at therapeutic doses, with transient injection-site reactions and facial flushing as the most common adverse effects. Dose titration guided by IGF-1 levels reduces the risk of supraphysiologic GH exposure. Stanley and Bhatt (2023) in the New England Journal of Medicine's review of growth hormone axis disorders noted that GH excess from exogenous sources carries long-term risks including glucose intolerance and acromegalic changes, reinforcing the case for periodic lab monitoring as part of medically supervised use.

Documentation Checklist Before You Submit

Collecting the right paperwork before submitting saves weeks of back-and-forth. Use this checklist:

• Prescription (copy from dispensing pharmacy, includes compound name, dose, clinician NPI)
• Pharmacy receipt (itemized, showing amount paid, date dispensed, compound name)
• Letter of Medical Necessity (signed, dated, includes ICD-10 code, clinical rationale, duration)
• Baseline labs to support the LMN (IGF-1, GH stimulation test result if available, or relevant metabolic panel)
• Your HSA/FSA administrator's compounded drug claim form (many have one; check your portal)

Missing any single item is the most common reason for delays. Pull the pharmacy receipt the day you pick up or receive the medication. Ask your HealthRX clinician to generate the LMN at the time of your prescription, not retroactively.